CSL share price cracks under Vifor Pharma acquisition delay

Regulatory delays are causing concern…

| More on:
A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is trading 2% lower at $270.63
  • Regulatory approval for the Vifor Pharma acquisition is now expected to be delayed by a few months
  • CSL remains confident the deal will go through

The CSL Limited (ASX: CSL) share price is being bled on Thursday amid delays to its big A$17.2 billion Vifor acquisition.

Shares in Australia's third-largest listed company are coming under pressure as investors absorb the latest information.

At the time of writing, CSL shares are trading 2% lower at $270.63 apiece. For context, the S&P/ASX 200 Index (ASX: XJO) is off the mark by 0.79% this morning.

Slower than first thought

When initially announced to shareholders in December last year, CSL expected the acquisition of Swiss therapeutics giant, Vifor Pharma, to be completed by June. However, as per today's announcement, this has fallen off track — pressuring the CSL share price.

According to the release, the original completion date will be pushed back due to the regulatory approval process. While no specific details were shared, the biotech behemoth now expects the process will take a few more months.

In the Vifor Pharma acquisition presentation provided in December, CSL outlined 'completion risk' as a key risk. This is where the company noted the deal requires foreign direct investment and other regulatory filings and approvals in certain key jurisdictions.

It appears some investors are cautious of the deal falling through. In turn, the CSL share price is weakening on the news today.

However, today CSL mentioned it remains confident in the deal being done.

CSL remains confident of completing its acquisition of Vifor Pharma AG and looks forward to expanding its presence in the rapidly growing nephrology market, as well as leveraging the companies' combined expertise to continue to deliver innovative solutions to rare and serious illness.

How has the CSL share price fared?

While the CSL share price has held up much better than some of its healthcare peers, the returns so far this year aren't exactly astounding.

Since the beginning of 2022, CSL shares have tumbled 8.5%. Although, this is far better than the 40% fall exhibited by Fisher & Paykel Healthcare Corp Ltd (ASX: FPH). Likewise, it is a welcomed return compared to the 20% dent to Ansell Limited (ASX: ANN).

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has recommended Ansell Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Mergers & Acquisitions

two men in business suits sit across from each other at a table with a chess board on it. Both hold their hands to their chins and look down in serious contemplation of their next move.
Resources Shares

'Not ruled out': Could BHP still buy Anglo-American?

This mega-deal might not be as dead as it looks.

Read more »

Happy couple looking at a phone and waiting for their flight at an airport.
Travel Shares

Flight Centre share price higher on acquisition news

The travel agent is betting big on cruises. Here's what you need to know.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Consumer Staples & Discretionary Shares

Myer and Premier Investments shares jump on huge merger news

The two retailers are combining some of their operations. Let's dig deeper into the plan.

Read more »

a woman drawing image on wall of big fish about to eat a small fish
Mergers & Acquisitions

Guess which $9 billion company is acquiring another ASX stock

This big fish is looking to acquire a small fish in a $45 million deal.

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Mergers & Acquisitions

TPG Telecom shares rise on $5.2b asset sale to Vocus

The telco is unlocking value by divesting assets. Here's what's happening.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Technology Shares

Why are Appen shares sinking today?

Let's see what is going on with this high-flying tech stock today.

Read more »

A silhouette shot of two business man shake hands in a boardroom setting with light coming from full length glass windows beyond them.
Mergers & Acquisitions

Rio Tinto share price rises on $10b Arcadium Lithium takeover deal

Management believes the deal makes it a global leader in energy transition commodities.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Mergers & Acquisitions

Arcadium Lithium shares rocket 46% on Rio Tinto takeover approach

The mining giant could soon become the third largest lithium supplier.

Read more »